Tumor Biology

, Volume 34, Issue 1, pp 403–413 | Cite as

Part III. Molecular changes induced by high nitric oxide adaptation in human breast cancer cell line BT-20 (BT-20-HNO): a switch from aerobic to anaerobic metabolism

  • H. De Vitto
  • B. S. Mendonça
  • K. M. Elseth
  • A. Onul
  • J. Xue
  • B. J. Vesper
  • C. V. M. Gallo
  • F. D. Rumjanek
  • W. A. Paradise
  • J. A. RadosevichEmail author
Research Article


Nutrient deprivation and reactive oxygen species (ROS) play an important role in breast cancer mitochondrial adaptation. Adaptations to these conditions allow cells to survive in the stressful microenvironment of the tumor bed. This study is directed at defining the consequences of High Nitric Oxide (HNO) exposure to mitochondria in human breast cancer cells. The breast cancer cell line BT-20 (parent) was adapted to HNO as previously reported, resulting in the BT-20-HNO cell line. Both cell lines were analyzed by a variety of methods including MTT, LDH leakage assay, DNA sequencing, and Western blot analysis. The LDH assay and the gene chip data showed that BT-20-HNO was more prone to use the glycolytic pathway than the parent cell line. The BT-20-HNO cells were also more resistant to the apoptotic inducing agent salinomycin, which suggests that p53 may be mutated in these cells. Polymerase chain reaction (PCR) followed by DNA sequencing of the p53 gene showed that it was, in fact, mutated at the DNA-binding site (L194F). Western blot analysis showed that p53 was significantly upregulated in these cells. These results suggest that free radicals, such as nitric oxide (NO), pressure human breast tumor cells to acquire an aggressive phenotype and resistance to apoptosis. These data collectively provide a mechanism by which the dysregulation of ROS in the mitochondria of breast cancer cells can result in DNA damage.


Breast cancer Nitric oxide p53 Reactive oxygen species (ROS) Glycolysis and apoptosis Aerobic and anaerobic metabolisms 


  1. 1.
    Siegel R, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.Google Scholar
  2. 2.
    Moller P, et al. Air pollution, oxidative damage to DNA, and carcinogenesis. Cancer Lett. 2008;266(1):84–97.PubMedCrossRefGoogle Scholar
  3. 3.
    Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29(5):625–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Paradise WA, et al. Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci. 2010;11(7):2715–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Ralph SJ, et al. The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation—why mitochondria are targets for cancer therapy. Mol Aspects Med. 2010;31(2):145–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Jenkins DC, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA. 1995;92(10):4392–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Bentz BG, et al. The yin and yang of nitric oxide: reflections on the physiology and pathophysiology of NO. Head Neck. 2000;22(1):71–83.PubMedCrossRefGoogle Scholar
  8. 8.
    De Vitto H, Mendonça BS, Elseth KM, et. al. Part II. Mitochondrial mutational status of high nitric oxide adapted cell line BT-20 (BT-20-HNO) as it relates to human primary breast tumors (submitted in conjunction with current manuscript). Tumor Biol. 2012. doi: 10.1007/s13277-012-0555-4.
  9. 9.
    Bentz BG, et al. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1999;108(8):781–7.PubMedGoogle Scholar
  10. 10.
    Radosevich JA, Elseth KM, Vesper BJ, et al. Long-term adaptation of lung tumor cell lines with increasing concentrations of nitric oxide donor. Open Lung Canc J. 2009;2:35–44.CrossRefGoogle Scholar
  11. 11.
    Vesper BJ, et al. Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide. Tumor Biol. 2010;31(4):267–75.CrossRefGoogle Scholar
  12. 12.
    Yarmolyuk YR, et al. Part I. Development of a model system for studying nitric oxide in tumors: high nitric oxide-adapted head and neck squamous cell carcinoma cell lines. Tumor Biol. 2011;32(1):77–85.CrossRefGoogle Scholar
  13. 13.
    Onul A, et al. Long-term adaptation of the human lung tumor cell line A549 to increasing concentrations of hydrogen peroxide. Tumor Biol. 2012; 33(3):739–48.Google Scholar
  14. 14.
    Scudellari M. Does mitochondrial dysfunction lie at the heart of common, complex diseases like cancer and autism? The Scientist. 2011;25:30–5.Google Scholar
  15. 15.
    Nelson DA, et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 2004;18(17):2095–107.PubMedCrossRefGoogle Scholar
  16. 16.
    Samper E, et al. Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. Free Radic Biol Med. 2009;46(3):387–96.PubMedCrossRefGoogle Scholar
  17. 17.
    Wong TS, et al. Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53. Nucleic Acids Res. 2009;37(2):568–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Lasfargues EY, Ozzello L. Cultivation of human breast carcinomas. J Natl Cancer Inst. 1958;21(6):1131–47.PubMedGoogle Scholar
  19. 19.
    Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth. 1983;65:55–63.CrossRefGoogle Scholar
  20. 20.
    Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115(1):61–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Petitjean A, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976;3(9):2303–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Cubillos-Rojas M, et al. Simultaneous electrophoretic analysis of proteins of very high and low molecular mass using tris-acetate polyacrylamide gels. Electrophoresis. 2010;31(8):1318–21.PubMedCrossRefGoogle Scholar
  24. 24.
    Vesper BJ, et al. Part I. Molecular and cellular characterization of high nitric oxide-adapted human breast adenocarcinoma cell line. Tumor Biol. doi: 10.1007/s13277-012-0530-0.
  25. 25.
    Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269–70.PubMedGoogle Scholar
  26. 26.
    Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010;20(1):51–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Rodriguez-Enriquez S, et al. Targeting of cancer energy metabolism. Mol Nutr Food Res. 2009;53(1):29–48.PubMedCrossRefGoogle Scholar
  29. 29.
    Secomb TW, et al. Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol. 1998;454:629–34.PubMedCrossRefGoogle Scholar
  30. 30.
    Fuchs D, et al. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009;390(3):743–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Sablina AA, et al. The antioxidant function of the p53 tumor suppressor. Nat Med. 2005;11(12):1306–13.PubMedCrossRefGoogle Scholar
  32. 32.
    Kim KY, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 2011;413(1):80–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351(6326):453–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Olivier M, Hainaut P, Borresen-Dale A. Prognostic and predictive value of TP53 mutations in human cancer, in 25 years of p53 research. In: Hainaut P, Wiman K, editors. Springer; 2005.Google Scholar
  35. 35.
    Tomita Y, et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem. 2006;281(13):8600–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Hagn F, et al. BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem. 2010;285(5):3439–50.PubMedCrossRefGoogle Scholar
  37. 37.
    Achanta G, et al. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 2005;24(19):3482–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78(6):915–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Loibl S, et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer. 2005;41(2):265–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Chatterjee A, Mambo E, Sindransky D. Mitochondrial DNA mutations in human cancer. Oncogene. 2006;25:4663–74.PubMedCrossRefGoogle Scholar
  41. 41.
    Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009;19(7):802–15.PubMedCrossRefGoogle Scholar
  42. 42.
    Ishikawa K, Takenaga K, Akimoto M, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008;320:661–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Kulawiec M, Owens KM, Singh KK. mtDNA G10398A variant in African-American women with breast cancer provides resistance to apoptosis and promotes metastasis in mice. J Hum Genet. 2009;54(11):647–54.PubMedCrossRefGoogle Scholar
  44. 44.
    Gupta PB, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645–59.PubMedCrossRefGoogle Scholar
  45. 45.
    Switzer CH, et al. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci. 2011;32(11):644–51.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • H. De Vitto
    • 1
    • 2
    • 3
    • 4
  • B. S. Mendonça
    • 1
  • K. M. Elseth
    • 2
    • 3
    • 4
  • A. Onul
    • 2
    • 3
    • 4
  • J. Xue
    • 2
    • 3
    • 4
  • B. J. Vesper
    • 2
    • 3
    • 4
  • C. V. M. Gallo
    • 5
  • F. D. Rumjanek
    • 1
  • W. A. Paradise
    • 2
    • 3
    • 4
  • J. A. Radosevich
    • 2
    • 3
    • 4
    Email author
  1. 1.Universidade Federal do Rio de Janeiro, IBqMRio de JaneiroBrazil
  2. 2.Center for Molecular Biology of Oral Diseases, College of DentistryUniversity of Illinois at ChicagoChicagoUSA
  3. 3.Jesse Brown VAMCChicagoUSA
  4. 4.Department of Oral Medicine and Diagnostic Sciences, College of DentistryUniversity of Illinois at ChicagoChicagoUSA
  5. 5.Universidade do Estado do Rio de Janeiro, IB, DECBRio de JaneiroBrazil

Personalised recommendations